Articles Referencing ABBV
Mason Hawkins Gives Mickey Mouse the Boot, First Quarter Sells in Review
5/15/2013, 11:28 am from GuruFocus in Investing
Demonstrating once again that emotion can never get in the way
of investing decisions, Guru Mason Hawkins of Southeastern Asset Management
determined in the first quarter of 2013 that, as the... Read >>
Dodge & Cox Buys Kraft and AbbVie
5/14/2013, 6:04 pm from GuruFocus in Investing
Classic value investors Dodge & Cox scour markets for the best
bargains, and in the first quarter, they found only two to their
liking: Kraft Foods Group Inc. ( KRFT ) and AbbVie... Read >>
Merck's Liptruzet Approved in the US - Analyst Blog
5/7/2013, 12:22 pm from Zacks.com in Investing, Business, Stocks
Merck ( MRK ) recently gained
US Food and Drug Administration (FDA) approval for its combination
cholesterol treatment, Liptruzet. The FDA granted approval to
Liptruzet for the treatment of... Read >>
Positive Opinion on Allergan Candidate - Analyst Blog
5/6/2013, 5:23 pm from Zacks.com in Investing, Business, Stocks
Allergan, Inc. ( AGN ) recently received
encouraging news when the US Food and Drug Administration's (FDA)
General and Plastic Surgery Devices Panel of the Medical Devices
Advisory... Read >>
Bayer Discontinues Hemophilia Study - Analyst Blog
5/6/2013, 5:23 pm from Zacks.com in Investing, Business, Stocks
Bayer 's ( BAYRY ) HealthCare
segment recently decided to discontinue the phase II/III TRUST
(TReatment with Unique recombinant rFVIIa STudy) study on BAY
86-6150. The study was evaluating... Read >>
Good News for Bristol-Myers - Analyst Blog
5/6/2013, 4:23 pm from Zacks.com in Investing, Business, Stocks
Bristol-Myers Squibb Company ( BMY ) recently received
positive news from the US Food and Drug Administration (FDA) when
the US regulatory authority approved the pharma major's HIV... Read >>
Covidien Provides 2013 Outlook - Analyst Blog
5/6/2013, 1:22 pm from Zacks.com in Investing, Business, Stocks
Covidien plc ( COV ) has revealed its
guidance for fiscal 2013 after adjusting for the spin-off of the
Pharmaceutical business, which is expected to take place at the end
of third quarter... Read >>
Earnings Plummet, Outlook Maintained at Sanofi - Analyst Blog
5/3/2013, 1:30 pm from Zacks.com in Investing, Business, Earnings, Stocks
Sanofi ( SNY ) reported first
quarter 2013 business earnings of 81 cents per American Depository
Share (ADS), below the Zacks Consensus Estimate of 89 cents.
Earnings were down 29.0% at... Read >>
Top Fund Buys Focus On Defensive Stocks, Housing
5/2/2013, 5:45 pm from Investor's Business Daily in Investing, Mutual Funds
April notched another month of gains for the stock market.
That's four straight months so far this year. But this market rally is getting long in the tooth and top fund
managers have been... Read >>
Actavis Beats on Earnings, Raises View - Analyst Blog
5/2/2013, 9:55 am from Zacks.com in Investing, Business, Earnings, Stocks
Actavis, Inc.'s ( ACT ) first quarter
2013 earnings of $1.99 per share beat the Zacks Consensus Estimate
of $1.87 and increased 21% from the year-ago earnings. Revenues for the reported... Read >>
Earnings and Sales Rise at Novo Nordisk - Analyst Blog
5/2/2013, 8:52 am from Zacks.com in Investing, Business, Earnings, Stocks
Novo Nordisk ( NVO ) reported first
quarter 2013 earnings of $1.94 per American Depository Receipt
(ADR), up 32.5% from the year-ago period. Revenues in the first
quarter of 2013... Read >>
Allergan Beats on Earnings - Analyst Blog
5/1/2013, 1:03 pm from Zacks.com in Investing, Business, Earnings, Stocks
Allergan, Inc. ( AGN ) reported first
quarter 2013 earnings of 98 cents per share, beating the Zacks
Consensus Estimate of 96 cents per share by 2 cents.
While earnings increased 18.1%... Read >>
Merck Earnings Decline Y/Y, Cuts Outlook - Analyst Blog
5/1/2013, 8:50 am from Zacks.com in Investing, Business, Earnings, Stocks
Merck & Co . ( MRK ) reported first
quarter 2013 earnings of 85 cents per share, well above the Zacks
Consensus Estimate of 78 cents. Tax benefits boosted first quarter
2013... Read >>
Merck - Pfizer in Diabetes Deal - Analyst Blog
4/30/2013, 3:51 pm from Zacks.com in Investing, Business, Stocks
Merck & Co., Inc. ( MRK ) recently
announced a strategic deal with Pfizer Inc. ( PFE ) for the
development and commercialization of Pfizer's ertugliflozin. The
companies will... Read >>
Bayer Aims to Expand HealthCare Portfolio - Analyst Blog
4/30/2013, 2:47 pm from Zacks.com in Investing, Business, Stocks
In a bid to strengthen its contraceptive portfolio
Bayer ( BAYRY ) inked a deal
to buy Conceptus Inc. ( CPTS ) for $31.00 per
share or approximately $1.1 billion in cash. Conceptus... Read >>